BUSINESS
    Janssen Primed to Join Japan Lung Cancer Market with Doublet Now under Review
    By Takashi Ebisawa April 26, 2024
    Johnson & Johnson’s Janssen Japan unit will make inroads into the lung cancer market, with a recently filed EGFR-targeted combination therapy expected to be its first product in this arena if approved.Kiran Patel, vice president…

    LATEST

    Astellas’ FY2023 Operating Profit Tumbles 80% Due to Iveric Bio Buyout
    April 26, 2024
    Astellas faced an 80% plunge in its operating profit for FY2023, affected by the acquisition of Iveric Bio and the amortization of intangible assets for Izervay (avacincaptad pegol), an age-related macular degeneration (AMD) treatment obtained from the US-based biotech.According to…
    Daiichi Sankyo Ups FY2025 Sales Goal to 2.1 Trillion Yen on Bullish Cancer Biz
    April 26, 2024
    Daiichi Sankyo said on April 25 that its revenue jumped 25% over the previous year in FY2023 ended March 2024, spurred by growth of its mainstay cancer drug and anticoagulant. On the back of its…
    MHLW’s Generic Industry Panel to Call for 5-Year Intensive Reform Period
    April 26, 2024
    A health ministry study group on the generic industry structure will urge the government to set a five-year period of intensive reform and create a roadmap of restructuring measures for the sector, according to its…

    COMMENTARY

    Can Japan Generic Industry Accelerate Self-Reform? MHLW Panel Debate Now in Homestretch
    By Izuru Ando

    Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…

    COLUMN

    Boosting Employee Retention in a Competitive Market
    By Philip Carrigan

    Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…

    MHLW Panel on Pharmaceutical Regulations

    Japan Set to Push Central IRBs for Clinical Trials, Avoid Customary All-Case PMS

    A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

    MHLW Panel on Generic Industry Structure

    Generic Firms Required to Disclose Supply Info from June after Pilot Rollout of Company Indicators
    By Izuru Ando

    Generic manufacturers in Japan will be required to disclose supply-related information from this June under a new company indicator rule…

    Drug Approval & Reimbursement in 2023

    Japan Approves Label Expansions for Rexulti, Rituxan, and More

    The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    MHLW Expert Panel on Comprehensive Policies

    Expert Panel Broadly OKs Draft Report on Pharma Policies, Further Deliberations by Other Forums
    By Yoshinori Sagehashi

    The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

    Chuikyo on Off-Year Drug Price Revision

    Healthcare Providers Rap Product Coverage of Off-Year Re-Pricing, Payers Hail Threshold: Chuikyo

    A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

    Jiho Survey: FY2022 Drug Price Revision

    Authorized Generics Likely Speeding Up G1/G2 Price Cuts for Off-Patent Brands: Jiho Tally

    Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

    FY2022 Drug Pricing Reform

    MHLW Unveils New List Prices for FY2022 Revision, 18 Off-Patent APIs Face Early “G1” Cuts

    Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA